Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Clinical and Radiological Activity After Extended Interval and Standard Interval Dosing of Ocrelizumab in Multiple Sclerosis: A Systematic Review and Meta-Analysis Publisher



Ghajarzadeh M1 ; Rastkar M2 ; Mowry EM1 ; Nourbakhsh B1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, United States
  2. 2. Multiple Sclerosis Research Group (MSRG), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences, Tehran, Iran

Source: Neurological Sciences Published:2025


Abstract

Background: Ocrelizumab is an anti-CD20 monoclonal antibody that is highly effective in reducing MS clinical and radiological activity. The standard dosing regimen consists of infusing 600 mg of ocrelizumab every six months. However, concerns about increasing risks of infection and lowered vaccine response, particularly during the COVID-19 pandemic, prompted clinicians to extend the dosing interval between ocrelizumab infusions for some patients. Several observational studies have compared the effects of extended-interval dosing (EID) and standardinterval dosing (SID) of ocrelizumab on MS relapse rate and MRI activity. Method: We performed a systematic review and meta-analysis of the current literature to summarize studies comparing ocrelizumab EID and SID on MS disease activity in patients with MS. Two independent reviewers searched PubMed, Scopus, EMBASE, Web of Science, and Google Scholar on the 1st of June 2024. Results: Our systematic search revealed 348 records, and after deleting duplicates, 29 records remained. Twenty-eight full texts were evaluated; ultimately, 16 studies remained for systematic review. In this meta-analysis, extended interval dosing (EID) was defined variably across studies, with some considering even a one-month delay as EID. The pooled odds ratios (ORs) for clinical and MRI activity, comparing ocrelizumab EID to SID groups, were estimated as 1.04 (95%CI: 0.67-1.6, I2=30%, P=0.21) and 1.31(95%CI: 0.90-1.92) (I2=15%, P=0.32), respectively. Conclusion: This systematic review and meta-analysis suggest that ocrelizumab EID is not associated with greater odds of clinical and radiological disease activity in patients with MS. © Fondazione Societa Italiana di Neurologia 2025.
Related Docs
View other Related Docs
1. De-Escalation of Anti-Cd20 Monoclonal Antibodies to Low-Moderate Efficacy Disease-Modifying Treatments (Dmts) in Patients With Relapse-Remitting Multiple Sclerosis: An Initial Iranian Experience, Caspian Journal of Internal Medicine (2025)
2. Consensus Recommendations for Diagnosis and Treatment of Multiple Sclerosis: 2023 Revision of the Menactrims Guidelines, Multiple Sclerosis and Related Disorders (2024)
3. Perspectives on the De-Escalation of Anti-Cd20 Monoclonal Antibodies in Patients With Multiple Sclerosis, Expert Opinion on Biological Therapy (2025)
4. Efficacy and Safety of Rituximab in Multiple Sclerosis: A Systematic Review and Meta-Analysis, Acta Neurologica Belgica (2023)
5. Association Between Disease-Modifying Therapies and Adverse Clinical Outcomes in Multiple Sclerosis Patients With Covid-19 Infection, Multiple Sclerosis and Related Disorders (2022)
6. Comparing Infusion-Related Reactions of the First Full Dose (600 Mg) Biosimilar Ocrelizumab Administration With the Standard Divided Protocol in Multiple Sclerosis Patients: A Randomized Controlled Trial Study, Acta Neurologica Belgica (2024)
7. Introduction to the Neuroimmunology of Multiple Sclerosis, Translational Neuroimmunology: Multiple Sclerosis: Volume 8 (2023)
8. Efficacy of Disease Modifying Therapies in Progressive Ms and How Immune Senescence May Explain Their Failure, Frontiers in Neurology (2022)
Experts (# of related papers)
View all Related Experts
Mohammad Ali Sahraian (6)
Nima Rezaei (3)
Other Related Docs
9. Current and Future Trends in Multiple Sclerosis Management: Near East Perspective, Multiple Sclerosis and Related Disorders (2023)
10. The Cost-Utility Analysis of Adding Ocrelizumab to the Treatment Plan for Primary Progressive Multiple Sclerosis in Iran, Expert Review of Pharmacoeconomics and Outcomes Research (2025)
11. The Prevalence and Odds of Bipolar Disorder in Women With Polycystic Ovary Syndrome (Pco) Disease: A Systematic Review and Meta-Analysis, Archives of Women's Mental Health (2024)
12. Impact of Gluten-Free Diet on Anthropometric Indicators in Individuals With and Without Celiac Disease: A Systematic Review and Meta-Analysis, Clinical Therapeutics (2023)
13. Consensus Recommendations for the Diagnosis and Treatment of Multiple Sclerosis: 2019 Revisions to the Menactrims Guidelines, Multiple Sclerosis and Related Disorders (2020)
14. Natural History of Cavernous Carotid Artery Aneurysms: A Systematic Review and Meta-Analysis, World Neurosurgery (2024)
15. Monoclonal Antibodies in Multiple Sclerosis Treatment, Translational Neuroimmunology: Multiple Sclerosis: Volume 8 (2023)
16. The Association Between Obesity and Polycystic Ovary Syndrome: An Epidemiologic Study of Observational Data, Journal of Clinical Endocrinology and Metabolism (2024)
17. Autoimmune Diseases, Clinical Immunology (2022)
18. B Cells in Multiple Sclerosis Therapy—A Comprehensive Review, Acta Neurologica Scandinavica (2018)
19. Vitamin D Therapy in Pediatric Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis, World Journal of Pediatrics (2023)
20. Impact of Gluten-Free Diet (Gfd) on Some of Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis, Journal of Nutritional Science (2024)